Ceftriaxone 1000 mg Sulbactam 500 mg, marketed as Triazo-S 1.5 mg, combines a third-generation cephalosporin antibiotic with a beta-lactamase inhibitor. Ceftriaxone inhibits bacterial cell wall synthesis, while Sulbactam inhibits beta-lactamase enzymes produced by some bacteria, enhancing Ceftriaxone's activity against beta-lactamase-producing strains. Triazo-S 1.5 mg is administered intravenously or intramuscularly to treat severe infections caused by susceptible Gram-positive and Gram-negative bacteria. It is prescribed under medical supervision, particularly in infections where beta-lactamase resistance is a concern, ensuring effective therapeutic outcomes.Available in PCD Franchise for injectable range and third party manufacturing.